Drug intelligence / Profile preview

NHL907

Development stage: Phase 1
Lead developer: NeuHyll Therapeutics
Administration: Oral

Overview

**NHL907** is an orally administered investigational drug being developed by NeuHyll. It is in a randomized, double-blind, placebo-controlled multiple-ascending-dose Phase 1 study in healthy adults to evaluate safety, tolerability, and pharmacokinetics. Its chemical composition, active components, molecular target, and mechanism of action have not been publicly disclosed in the available trial record.

Other names: NHL-907NHL907NHL 907

Beyond the preview

Go deeper on NHL907.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NHL907.

Explore the full profile